TS
VRTX icon

Triglav Skladi’s Vertex Pharmaceuticals VRTX Stock Holding History

Triglav Skladi’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.54M Hold
3,450
– – 0.11% 102
2025
Q4 		$1.56M Hold
3,450
– – 0.1% 103
2025
Q3 		$1.35M Hold
3,450
– – 0.09% 97
2025
Q2 		$1.54M Hold
3,450
– – 0.11% 92
2025
Q1 		$1.67M Hold
3,450
– – 0.14% 79
2024
Q4 		$1.39M Buy
+3,450
New +$1.6M 0.11% 94

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Triglav Skladi's VRTX Position: Q1 2026 in Review

Triglav Skladi held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 3,450 shares worth $1.54M. The position accounts for 0.11% of the portfolio, ranked #102.

Triglav Skladi first reported a position in VRTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.67M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Triglav Skladi held 3,450 shares of Vertex Pharmaceuticals worth $1.54M as of Q1 2026.
  • Triglav Skladi left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
  • Vertex Pharmaceuticals made up 0.11% of Triglav Skladi's portfolio in Q1 2026, its #102 holding.
  • Triglav Skladi first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • Triglav Skladi's Vertex Pharmaceuticals position peaked at $1.67M in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Triglav Skladi's 13F filing for Q1 2026, filed 4 May 2026.